Genentech is working with the FDA to launch a Phase III study comparing tocilizumab (Actemra) vs. standard of care in hospitalized adult patients with severe COVID-19 pneumonia. The trial hopes to open in April 2020 and test 330 patients. The trial endpoints include clinical status, mortality, mechanical ventilation and ICU variables.

Tocilizumab is the first humanized interleukin-6 (IL-6) drug originally approved for rheumatoid arthritis and is now being tested in COVID-19 patients to reduce lung inflammation. The IV version is also approved for patients who have CAR T cell induced cytokine release syndrome (which includes many multiple myeloma patients.). High IL-6 levels can cause damaging inflammation and tocilizumab blocks the effects of IL-6.

According to Randy Cron, MD, PhD, an expert in cytokine release syndrome, some of the severely ill coronavirus patients have lab features of CRS, also sometimes called cytokine storm syndrome (CSS).

Scientists sequenced the genomes of eight coronavirus strains circling the globe providing hints about the effectiveness of efforts to halt the virus.

Newborns and babies have so far seemed to be largely unaffected by the coronavirus, but three new studies suggest that the virus may reach the fetus in utero.

Even in these studies, the newborns seemed only mildly affected, if at all — which is reassuring, experts said. And the studies are small and inconclusive on whether the virus does truly breach the placenta.

“I don’t look at this and think coronaviruses must cross across the placenta,” said Dr. Carolyn Coyne of the University of Pittsburgh, who studies the placenta as a barrier to viruses. She was not involved in the new work.

Using transmission electron microscopy (TEM), scientists from the Indian Council of Medical Research (ICMR), managed to image the novel Coronavirus. The image was taken from the throat swab sample of the first laboratory-confirmed novel Coronavirus patient in India.

Scientists tested a total of seven negative-stained virus particles having features of Coronavirus-like particles from the sample.

The novel Coronavirus, which originated in China late last year, has caused a pandemic across the world.

Moderate consumption of marijuana doesn’t adversely affect lung function, according to a study.

A study published in 2012 in The Journal of the American Medical Association (JAMA) had some good news for people who smoke marijuana: smoking at a rate of one joint a day for as long as seven years doesn’t seem to affect lung function adversely.

Abbott Laboratories won U.S. Food and Drug Administration approval for its molecular test for the Coronavirus strain COVID-19, which the company says can deliver “positive results in as little as five minutes and negative results in 13 minutes.”

The FDA’s “emergency use authorization” awarded to Abbott’s ID NOW COVID-19 test is the latest in a growing number of agency approvals for more rapid molecular “point-of-care” diagnostic tests that can be used in temporary screening locations, doctor’s office labs and nursing homes to detect the Coronavirus strain COVID-19 within a half hour.

“With rapid testing on ID NOW, healthcare providers can perform molecular point-of-care testing outside the traditional four walls of a hospital in outbreak hotspots,” Abbott president and chief operating officer Robert Ford said.

Mexican authorities admit the number is far higher than previously estimated as murders continue to rise.

There’s a new COVID-19 test from healthcare technology maker Abbott that looks to be the fastest yet in terms of producing results, and that can do so on the spot right at point-of-care, without requiring a round trip to a lab. This test for the novel coronavirus causing the current global pandemic has received emergency clearance for use by the U.S. Food and Drug Administration, and will begin production next week, with output of 50,000 per day possible starting next week.

The new Abbott ID NOW COVID-19 test uses the Abbott ID NOW diagnostics platform, which is essentially a lab-in-a-box that is roughly the size of a small kitchen appliance. It’s size, and the fact that it can produce either a positive result in just five minutes, or a negative one in under 15, mean that it could be a very useful means to extend coronavirus testing beyond its current availability to more places including clinics and doctor’s offices, and cut down on wait times both in terms of getting tested and receiving a diagnosis.

Unlike the rapid tests that have been used in other countries, and that received a new type of authorization under an FDA guideline that doesn’t confirm the accuracy fo the results, this rapid testing solution uses the molecular testing method, which works with saliva and mucus samples swabbed from a patient. This means that it works by identifying a portion of the virus’ DNA in a patient, which means it’s much better at detecting the actual presence of the virus during infection, whereas other tests that search the blood for antibodies that are used in point-of-care settings can only detect antibodies, which might be present in recovered patients who don’t actively have the virus.